ACTIVE

ReWind Therapeutics

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-4,6 M €+2,3 %over 1 year
Gross margin-528,3 k €-338,2 %over 1 year
Equity-2,6 M €+70,3 %over 1 year
Workforce4,9 ETP-43,0 %over 1 year

Identity

Source · BCE/KBO

ReWind Therapeutics is a Public limited company incorporated in 2017. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven. It employs on average 4,9 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0682.626.216
Incorporation
06/10/2017
Legal form
Public limited company
Registered office
Gaston Geenslaan 3
3001 Leuven · FlandreSee on map
Contributed capital
2 755 035,17 €
Latest accounts
31/12/2025
Average workforce
4,9 ETP
Joint committees (1)
  • 207
Signals
Healthy social debts

Financials

Source · NBB, 9 filings

Trend over 7 financial years

20252024202320222021
Income statement
Gross margin-528,3 k €-120,5 k €-241,8 k €-294,5 k €678,7 k €
EBITDA-1,2 M €-1,2 M €-1,3 M €-1,2 M €83,6 k €
Operating result-4,3 M €-4,1 M €-5,4 M €-4,5 M €-3 M €
Net result-4,6 M €-4,7 M €-5,7 M €-4,5 M €-2,9 M €
Balance sheet
Equity-2,6 M €-8,8 M €-4 M €1,6 M €6,1 M €
Total assets2,1 M €2,7 M €3,6 M €6,2 M €6,5 M €
Cash1,3 M €1,6 M €2,5 M €5,2 M €4,9 M €
Debts4,4 M €11,5 M €7,6 M €4,5 M €392,4 k €
Other
Workforce4,9 ETP8,6 ETP9,6 ETP7,7 ETP6,0 ETP

Board of directors

Source · NBB, accounts to 31/12/2025

8 active · 8 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Paul Nicklin
Directorsince 17/03/2025
BIOSKILLS0525.916.875Represented by Jim VAN HEUSDEN
Chairman of the board of directors27/02/2018 → 16/05/2030
Cornelis Been
Director01/08/2020 → 16/05/2030
Participatiemaatschappij Vlaanderen0455.777.660Represented by Tobias Wilms
Director06/05/2020 → 16/05/2030
Bauke Anninga
Director07/12/2023 → 16/05/2030
Claus Asbjorn Andersson
Director27/01/2023 → 26/01/2029
Stefaan Allemeersch
Director29/09/2017 → 20/05/2027
Stefan Lohmer
Director29/09/2017 → 20/05/2027

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Anhabio Consulting GmbHRepresented by Anja Harmeier
Persoon belast met dagelijks bestuur20/09/2021 → 2024 accounts
Sebastian Kreuz
Director26/09/2019 → 2023 accounts
James KASUBOSKI
Director11/06/2019 → 23/09/2019
Cheryl Zimberlin
Director12/02/2019 → 07/12/2023

Other companies at this address

Gaston Geenslaan 3 3001 Leuven
CompanyCBE no.
AstriVax Therapeutics● Active
0787.990.881
AUGUSTINE THERAPEUTICS● Active
0722.705.230
COULTREON BIOPHARMA● Active
1019.429.814
K5 Therapeutics● Active
0757.718.072
Metaptys● Active
0554.664.311
Montis Biosciences● Active
0730.979.429
Perseus Biomics● Active
0650.946.412
QUOMAK● Active
0448.488.111
Stichting Administratiekantoor Coultreon● Active
1040.853.946
Tavira Therapeutics● Active
0802.591.262
VEDRA THERAPEUTICS● Active
1039.565.628

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date08/07/202626/05/202517/05/202431/05/202331/08/202217/06/2021
General meeting30/06/202615/05/202516/05/202422/05/202327/06/202210/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 9 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202530/06/202608/07/2026DutchPDF
Abridged model31/12/202415/05/202526/05/2025DutchPDF
Abridged model31/12/202316/05/202417/05/2024DutchPDF
Abridged model31/12/202222/05/202331/05/2023DutchPDF
Abridged modelCorrection31/12/202127/06/202231/08/2022DutchPDF
Abridged model31/12/202119/05/202230/06/2022DutchPDF
Abridged model31/12/202010/06/202117/06/2021DutchPDF
Abridged model31/12/201922/05/202008/06/2020DutchPDF
Micro model31/12/201816/05/201906/06/2019DutchPDF

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

8 active · 8 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Paul Nicklin
Directorsince 17/03/2025
BIOSKILLS0525.916.875Represented by Jim VAN HEUSDEN
Chairman of the board of directors27/02/2018 → 16/05/2030
Cornelis Been
Director01/08/2020 → 16/05/2030
Participatiemaatschappij Vlaanderen0455.777.660Represented by Tobias Wilms
Director06/05/2020 → 16/05/2030
Bauke Anninga
Director07/12/2023 → 16/05/2030
Claus Asbjorn Andersson
Director27/01/2023 → 26/01/2029
Stefaan Allemeersch
Director29/09/2017 → 20/05/2027
Stefan Lohmer
Director29/09/2017 → 20/05/2027

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Anhabio Consulting GmbHRepresented by Anja Harmeier
Persoon belast met dagelijks bestuur20/09/2021 → 2024 accounts
Sebastian Kreuz
Director26/09/2019 → 2023 accounts
James KASUBOSKI
Director11/06/2019 → 23/09/2019
Cheryl Zimberlin
Director12/02/2019 → 07/12/2023

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Capital / shares13/08/2026
    KAPITAAL, AANDELEN, STATUTEN (VERTALING, COORDINATIE,
    PDF
  • Mandates13/03/2026
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates17/09/2025
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates16/04/2025
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Capital / shares10/03/2025
    KAPITAAL - AANDELEN
    PDF
  • Mandates29/08/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates03/01/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates04/04/2023
    MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts
Year
Identity
Incorporation
Name
Registered office
Annual accounts
Filings7 filings
Mandates
Paul Nicklin
Participatiemaatschappij Vlaanderen
BIOSKILLS
Cornelis Been
Bauke Anninga
Claus Asbjorn Andersson
Stefaan Allemeersch
Stefan Lohmer
Anhabio Consulting GmbH
Sebastian Kreuz
James KASUBOSKI
Cheryl Zimberlin
20172018201920202021202220232024202520262027202820292030
ReWind Therapeutics
Gaston Geenslaan 3, 3001 Heverlee
Director
Director
Chairman of the board of directors
Director
Director
Director
Director
Director
Persoon belast met dagelijks bestuur
Director
Director
CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE
Registered addressPeriodSource
Gaston Geenslaan 3, 3001 HeverleeCurrent
accounts 2022 → 2025
Accounts 2025 · 2026-00276944
Gaston Geenslaan 2, 3001 Heverlee
accounts 2021
Accounts 2021 · 2022-20420415

Company names

Source · NBB annual accounts, CBE
NamePeriodSource
ReWind TherapeuticsCurrent
accounts 2019 → 2025
Accounts 2025 · 2026-00276944

Events

  1. 2025
    Annual accounts 2025-4,6 M €↑
  2. 2024
    Annual accounts 2024-4,7 M €↑
  3. 2023
    Annual accounts 2023-5,7 M €↓
  4. 2022
    Annual accounts 2022-4,5 M €↓
  5. 2021
    Annual accounts 2021-2,9 M €↑
  6. 2020
    Annual accounts 2020-3,5 M €↓
  7. 2019
    Annual accounts 2019-2,3 M €
  8. 06/10/2017
    IncorporationPublic limited company